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Abstract
Barrett’s oesophagus is the only known precursor to oesophageal adenocarcinoma (OAC). Although guidelines on the 
screening and surveillance exist in Barrett’s oesophagus, the current strategies are inadequate. Oesophagogastroduoden-
oscopy (OGD) is the gold standard method in screening for Barrett’s oesophagus. This invasive method is expensive with 
associated risks negating its use as a current screening tool for Barrett’s oesophagus. This review explores current defini-
tions, epidemiology, biomarkers, surveillance, and screening in Barrett’s oesophagus. Imaging modalities applicable to this 
condition are discussed, in addition to future developments. There is an urgent need for an alternative non-invasive method 
of screening and/or surveillance which could be highly beneficial towards reducing waiting times, alleviating patient fears 
and reducing future costs in current healthcare services. Vibrational spectroscopy has been shown to be promising in cat-
egorising Barrett’s oesophagus through to high-grade dysplasia (HGD) and OAC. These techniques need further validation 
through multicentre trials.
Keywords Barrett’s oesophagus · Imaging modalities · Oesophageal adenocarcinoma · Screening
Introduction
Oesophageal adenocarcinoma (OAC) has now replaced 
squamous cell carcinoma (SCC) as the most common type of 
oesophageal malignancy in the Western world [1, 2]. OAC 
is aggressive and usually presents late with a poor progno-
sis with an overall 5-year survival below 25% [3]. Despite 
technological enhancements related to preventative strate-
gies and more effective combination therapies, the overall 
incidence of oesophageal adenocarcinoma has risen [4].
There is a proven association between adenocarcinoma 
and Barrett’s oesophagus, a condition that appears to arise 
in response to chronic inflammation from gastro-oesopha-
geal reflux disease (GORD) [5]. Reflux induces metaplasia, 
which in turn leads to high-grade dysplasia (HGD) and inva-
sive OAC. Barrett’s oesophagus is the only known precursor 
to OAC to date and has a small prevalence in the European 
population (up to 2%) [6]. General surveillance through 
oesophagogastroduodenoscopy (OGD) of all individuals 
with Barrett’s oesophagus is not cost-effective as the annual 
incidence of oesophageal adenocarcinoma developing in 
Barrett’s is only 0.33% [7, 8]. This highlights the need to 
adapt surveillance programs to include individuals with Bar-
rett’s at high absolute risk of tumour progression.
There remains a lack of consensus regarding the natural 
history of Barrett’s oesophagus [9]. Furthermore, there is 
a lack of reliable predictive biomarkers that might enable 
us to risk stratify Barrett’s oesophagus patients [10, 11]. 
Prospective studies have not established a survival benefit 
for screening and surveillance [9]. All present guidelines 
regarding screening, surveillance and management fail to 
demonstrate clear evidence for an established benefit and 
cost-effectiveness of surveillance, and robust risk stratifica-
tion for patients to best use health resources [12].
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Historical perspective and definition
Australian-born surgeon Norman Rupert Barrett first 
developed the term ‘Barrett’s Oesophagus’ in patients with 
ulcerations in a tubular organ suggestive of an oesophagus, 
but whose distal, ulcerated portion was lined by columnar 
epithelium [13]. Bosher and Taylor elaborated on Mr. Bar-
rett’s definition describing intestinal type goblet cells in 
the columnar-lined oesophagus in 1951 [14]. Morson and 
Belcher reported the first case of malignancy related to 
Barrett’s oesophagus in 1952. The case was of a patient 
who developed an adenocarcinoma in oesophageal mucosa 
that presented ‘atrophic changes with a tendency towards 
intestinal type containing many goblet cells [15].
The definition of Barrett’s oesophagus is controversial 
and worldwide professional societies have different defini-
tions related to endoscopic documentation of columnar-
lined mucosa (Table 1). The presence of specialised intes-
tinal metaplasia (SIM) characterised by the presence of 
goblet cells is important in its definition. SIM is associated 
with the risk of progression to low-grade dysplasia (LGD), 
high-grade dysplasia (HGD) and adenocarcinoma (OAC).
Endoscopic evaluation
The significant anatomical landmark in Barrett’s oesopha-
gus identification is the oesophagogastric junction (OGJ). 
This is usually identified as the proximal extent of the 
upper gastric folds. The squamocolumnar junction (Z line) 
is the point at which squamous mucosa of the oesophagus 
meets the columnar mucosa of the stomach. Irregularity of 
the Z line is defined as <1 cm non-circumferential tongues 
of columnar mucosa at the squamocolumnar junction. This 
is not currently defined as Barrett’s oesophagus [16] but in 
up to 40% of such cases histopathology will reveal intes-
tinal metaplasia (IM).
Barrett’s oesophagus was initially characterised into 
short- and long-segment disease (< or >3  cm) based 
on endoscopic metaplastic epithelial findings [19]. The 
Prague ‘C’ and ‘M’ classification takes the circumferential 
(C) and maximum (M) tongue extent of the endoscopically 
visualised Barrett’s above the OGJ into account (Fig. 1; 
Table 2).
The sensitivity of endoscopic examination for the diagno-
sis of Barrett’s oesophagus increases with increasing length 
[20]. The overall prevalence of short-segment Barrett’s 
Table 1   Worldwide 
professional societies’ 
definitions of Barrett’s 
oesophagus
ACG American College of Gastroenterology, BSG British Society of Gastroenterology, AGA American 
Gastroenterological Association, SFED Société Française d’Endoscopie Digestive
ACG (USA) [9] BSG (England) 
[16]
AGA (USA) 
[17]
SFED 
(France) 
[18]
Intestinal metaplasia (biopsies) Yes Yes Yes Yes
Endoscopic documentation of 
columnar-lined mucosa
Yes No Yes Yes
Fig. 1   Illustration showing ‘C’ and ‘M’ measurements.  Adapted 
from https ://www.endos copy-campu s.com/en/klass ifika tione n/prag-
klass ifika tione n-des-barre tt-oesop hagus / (accessed 16th October 
2019)
Table 2   Vienna classification of epithelial neoplasia of the digestive 
tract [45]
Category Classification
1 Negative for neoplasia/dysplasia
2 Indefinite for neoplasia/dysplasia
3 Non-invasive low-grade neoplasia
Low-grade adenoma/dysplasia
4 Non-invasive high-grade neoplasia
4.1 High-grade adenoma/dysplasia
4.1 Non-invasive carcinoma (carcinoma in situ)
4.1 Suspicion of invasive carcinoma
5 Invasive neoplasia
5.1 Intramucosal carcinoma
5.2 Submucosal carcinoma or beyond
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oesophagus is greater than long-segment Barrett’s oesopha-
gus in studies where biopsies are systematically taken using 
established protocols [21]. The overall reliability of endo-
scopic examination and biopsy is approximately 80%. Given 
the inter-observer variability of diagnosing short segments, 
especially those <1 cm, and the exclusion of this length from 
some studies, it is uncertain whether segments <1 cm are 
associated with an increased risk of OAC (Fig. 2) [22].
Risk factors and epidemiology
Males in their 6th decade of life are twice as likely to have a 
diagnosis of Barrett’s oesophagus than females [23]. White 
subjects have a 4–6 times higher incidence of the disease 
compared to black subjects [24]. Other risk factors such as 
chronic GORD, reduced Helicobacter pylori and central 
obesity also increase the risk of Barrett’s oesophagus in mul-
tiple studies [25]. Alcohol consumption does not appear to 
be a strong risk factor.
The worldwide increase in GORD is accompanied by 
a rapid increase in prevalence of Barrett’s oesophagus, 
the main target for prevention of OAC [25]. The exact 
prevalence in different populations is difficult to assess as 
the condition is asymptomatic, and a diagnosis is made 
only when an endoscopy is performed [26]. The latter is 
usually performed for persistent GORD symptoms [26]. 
The prevalence of Barrett’s oesophagus in the unselected 
general population is between 1 and 2% in European stud-
ies and approximately 5–6% in the United States [27].
Further population-based studies have provided fur-
ther insight into the prevalence of Barrett’s oesophagus. 
The Swedish Kalixanda study found that up to 10.3% of 
patients with GORD symptoms had an endoscopic Bar-
rett’s oesophagus segment [6]. In an Italian study of 1033 
patients, histology confirmed the presence of columnar 
epithelium in 3.6%, while specialised intestinal metaplasia 
was observed in 1.6% of them [3]. Further UK-detailed 
studies on age- and sex-related distribution of Barrett’s 
oesophagus prevalence have observed that the prevalence 
of Barrett’s oesophagus increased with 7.4% for each addi-
tional year of age between the age of 20 and 59 year in 
males. It showed a similar pattern though with a 20-year 
delay in the female population [28]. In a meta-analysis of 
23 studies from Asia, the prevalence of endoscopically 
diagnosed Barrett’s oesophagus was 7.8% with histologi-
cally confirmed Barrett’s in 1.6% [29]. The prevalence of 
LGD, HGD and adenocarcinoma in cases with histologi-
cally proven BO was 6.9%, 3.0 and 2.0%, respectively [29]. 
In studies from the United States of America rates are 
1.3–9.8%, 0–5.3% and 1.3–5.7%, respectively [30].
Fig. 2   Endoscopic visualisation of a Barrett’s segment, b Barrett’s with LGD and HGD, c OAC
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Natural history and progression to OAC
It has been shown that specialised intestinal metaplasia aris-
ing in Barrett’s oesophagus is a risk factor for progression 
to cancer. A meta-analysis from 2012 including 57 studies 
(n = 11,434 patients) reports an annual incidence of oesoph-
ageal adenocarcinoma developing in Barrett’s oesophagus 
of 0.33% (95% CI 0.28–0.38%) [7]. Patients with Barrett’s 
oesophagus are ten times more likely to die from other 
causes than oesophageal cancer. It appears that men progress 
to cancer at twice the rate of women, patients with short-
segment Barrett’s oesophagus are least likely to progress 
and those with dysplasia at index biopsy are the most likely 
to progress [7].
Progression rates to dysplasia and adenocarcinoma were 
initially established from a Dutch cohort study in Rotterdam. 
One hundred and sixty-six patients were recruited from 1973 
to 1983, and endoscopic surveillance was started from 2001. 
Thirteen patients (M/F 10/3) developed HGD or OAC during 
follow-up. These were all symptomatic cases of HGD/OAC 
as the patients were not under endoscopic surveillance and 
were only reinvestigated for symptoms. These cases were 
observed over a period of 1967 patient years, 1 per 151 years 
of follow-up or 0.66 per annum (95% CI 0.58–0.74) [31].
Subsequent meta-analyses and systematic reviews from 
2007 to 2017 report progression rates to adenocarcinoma 
ranging from 2.2 to 6.3 per 1000 patient years when focus-
ing on all patients with Barrett’s oesophagus [32–34] Singh 
et  al. [30] conducted a systematic review of 24 studies 
(N = 2694). This concluded an annual progression rate of 
Barrett’s oesophagus to adenocarcinoma of 5.4 (3.2–7.6) per 
1000 years.
Current literature is reliant upon a single pathologist’s 
interpretation of the histology. Since the diagnosis of dyspla-
sia is investigator dependent, more rigorous criteria ask for 
confirmation of dysplasia by a second histopathologist. Sub-
sequently, a proportion of patients are down-staged which 
may affect epidemiological studies [26]. Kestens et al. [35] 
re-assessed low-grade dysplastic samples of 231 Barrett’s 
oesophagus patients. LGD was confirmed in 161 (70%); the 
remainder was mostly downgraded to no dysplasia or indefi-
nite for dysplasia. A recent systematic review and meta-anal-
ysis conducted in 2017 confirmed that the risk of progres-
sion to HGD or OAC in Barrett’s oesophagus patients were 
primarily determined by the presence or absence of LGD 
[OR 4.2 (2.1–8.5)] [36].
Patients with GORD can subsequently develop Barrett’s 
oesophagus and go on to develop LGD, HGD and OAC. 
At an early stage, these conditions can be treated by abla-
tive and minimally invasive techniques with limited risk. 
However, at an advanced stage, OAC requires invasive treat-
ment with considerable burden, financial cost, and mortality 
[26]. Early detection and prevention are the key strategies to 
manage OAC. The argument as to which Barrett’s oesopha-
gus patients are most likely to benefit from surveillance and 
management centres on the high prevalence of Barrett’s 
oesophagus and the low cancer incidence amongst Barrett’s 
oesophagus cases. This should be weighed up against the 
burden of invasive treatment and the high mortality in OAC 
[26].
With the overall risk of OAC in Barrett’s oesophagus 
being low, patients are often middle-to-older ages with obe-
sity and metabolic syndrome. Many patients will succumb to 
another condition. This is often not conveyed to patients and 
many live-in fear of developing malignancy disproportionate 
to their definite risk. This point further highlights the need 
to adapt surveillance programs to include individuals with 
Barrett’s at high absolute risk of tumour progression.
Histopathology
For a non-suspicious segment undergoing routine surveil-
lance, mapping biopsies should be taken at 2-cm intervals 
from each quadrant as well as separate biopsies from the 
anatomic cardia. For dysplastic segments, biopsies should 
be taken at 1-cm intervals. This so-called Seattle protocol 
increases the yield of both low-grade and high-grade dys-
plasia by 17 and 3%, respectively, compared with random 
biopsies [37]. A minimum of eight biopsies are required to 
provide an adequate degree of histological confirmation in 
Barrett’s oesophagus [38].
In patients with Barrett’s oesophagus <3 cm and no meta-
plasia or dysplasia, a repeat endoscopic assessment with 
quadrantic biopsies is recommended as an extra measure 
to try to establish the diagnosis, as only patients with SIM 
should undergo further surveillance [16]. In patients with 
long-segment disease (>3 cm), SIM is almost always found. 
Targeted biopsies from any lesions and the immediately sur-
rounding epithelium should be taken separately. Targeted 
biopsies alone are not a substitute for mapping biopsies as 
up to 20% of lesions may not be easily visible with white 
light endoscopy. Histopathological definitions of Barrett’s 
oesophagus vary worldwide [39]. The requirement of SIM 
has been supported by studies that have claimed intesti-
nal metaplasia to be a prerequisite for the development of 
adenocarcinoma. Goblet cells may be identified on routine 
histological stains (haematoxylin and eosin, H&E), although 
many institutions routinely employ PAS-Alcian Blue stains 
to highlight acidic mucin in goblet cells.
Intestinal metaplasia of gastric cardia does not compare 
to Barrett’s oesophagus and may be less likely to progress 
to dysplasia [40, 41]. A diagnosis of Barrett’s oesophagus, 
therefore, cannot be made histologically when the exact site 
of biopsy of the metaplastic fragment is not known. Bar-
rett’s oesophagus is defined as a clinicopathologic diagno-
sis with the biopsy taken from an endoscopically visualised 
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salmon-coloured irregularity in the oesophagus. SIM may 
be either “complete” (when goblet cells are accompanied by 
absorptive and/or Paneth cells) or “incomplete” (absence of 
absorptive and/or Paneth cells) [11].
Intestinal metaplasia shows inflammatory changes and 
becomes dysplastic. Dysplasia is assessed in columnar 
mucosa, and biopsies are categorised as being ‘negative for 
dysplasia’ if the cells show maturation towards the surface 
in the form of decreasing nuclear size, decreasing nuclear 
hyperchromasia and increasing cytoplasmic volume [11]. 
There may be histological changes deemed insufficient to 
characterise as dysplasia, categorised as ‘indefinite for dys-
plasia’ (Fig. 3).
Barrett’s adenocarcinoma develops through a multistep 
process with progressive worsening of a precursor lesion 
defined as dysplasia. In LGD, the molecular architecture is 
preserved or minimally abnormal, nuclei are elongated and 
crowded at the base but not at apex of cells, pseudo-stratifi-
cation may be extensive, there may be nuclear enlargement, 
and surface villous transformation may be present [11]. The 
differentiation of LGD from non-dysplastic tissue is diffi-
cult to establish with regards to subjective histopathological 
criteria (Fig. 4).
High-grade intestinal type dysplasia demonstrates mark-
edly atypical features including cytologic atypia, nuclear 
stratification to surface of cell with loss of polarity, and 
nuclei which are no longer radially oriented [42]. OAC 
shows marked atypia with no radially orientated nuclei 
(Figs. 5, 6).
Progressive histological changes are subtle hence result-
ing in intra- and inter-observer variation in the diagnosis 
of dysplasia in Barrett’s oesophagus. There are no clearly 
defined cut-off points that distinguish disease progression 
when comparing LGD and HGD. Furthermore, sampling 
errors can occur with small dysplasia sizes and its patchy 
distribution. Literature from this century has compared gen-
eral and specialist gastrointestinal pathologists. In a Dutch 
study by Kerkhof et al. [43], general histopathologists were 
found to over diagnose HGD. Up to 40% of patients initially 
diagnosed with HGD by a general pathologist were down-
graded (11% no dysplasia, 12% indefinite for dysplasia, 16% 
LGD) when the samples were reviewed by three experienced 
gastrointestinal (GI) pathologists [43].
Montgomery et al. [44] rigorously tested criteria, assess-
ing intra-observer and inter-observer reproducibility. When 
Fig. 3   Photomicrograph of intestinal metaplasia (H&E ×100 objec-
tive)
Fig. 4   Photomicrograph of low-grade dysplasia (H&E ×100 objec-
tive)
Fig. 5   Photomicrograph of high-grade dysplasia (H&E ×100 objec-
tive)
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a four-tier grading system was employed (non-dysplastic/
indefinite and low grade/high grade/cancer), the kappa index 
was low (0.43). Kappa improved (0.66) when a simplified 
classification was used (non-dysplastic/indefinite and low 
grade/high grade and cancer). These results emphasise the 
need to obtain a second opinion on problematic cases [44]. 
Geographical discrepancies are also highlighted in the lit-
erature. In a study comparing Western and Japanese patholo-
gists (N = 21), 14 lesions were classified as adenocarcinoma 
by Western pathologists, compared to 19 of the same lesions 
by those from Japan [45]. The ‘Vienna classification’ was 
proposed for standardisation. Although this classification 
system is widely used, it is qualitative and does not take 
disease progression into account.
Molecular and genetic advances
Mutations within Barrett’s oesophagus segments develop 
over time even in non-dysplastic epithelium. Increased 
clonal diversity is a marker for progression to dysplasia 
[46]. Clonal populations are stable over time, indicating 
that the dysplastic potential of Barrett’s oesophagus may be 
pre-determined. This implies that if this potential could be 
accurately determined at the index endoscopy, then further 
surveillance or therapies could be targeted only to those with 
dysplastic potential [47, 48].
Reflux injury appears to be key in the pathogenesis to 
OAC. Duodenogastric acid and contents reflux including 
unconjugated bile acids such as deoxycholate, can upregu-
late pro-inflammatory cytokines including IL-1β, IL-6, IL-8, 
and related transcription factors, notably NFκB that are rel-
evant to metaplasia, dysplasia and cancer, and resistance to 
apoptosis [49–51].
Studies have demonstrated that there is a loss of both 
tumour suppressors p16 and p53 [52, 53]. As well as point 
mutations, aneuploidy has an important role in the progres-
sion of Barrett’s oesophagus to OAC [54–56]. Su et al. [57] 
reported that variants in the major histocompatibility com-
plex (MHC) locus and at chromosome 16q24.1 locus, near 
FOXF1, predispose to Barrett’s oesophagus. Levine et al. 
[58] identified three gene associations (FOXF1, 19p13 in 
CRTC1, 3p14 near FOXP1) that were implicated in oesopha-
geal cancer development from Barrett’s oesophagus.
Both Barrett’s oesophagus and OAC are characterised by 
a loss of heterozygosity (LOH), aneuploidy, specific genetic 
mutations, and clonal diversity [59]. There is currently ongo-
ing research into establishing panel genetics and epigenetics 
involved in Barrett’s oesophagus and its progression to OAC.
Field effect
Numerous previous studies from the 1980s and 1990s have 
demonstrated multifocal high-grade dysplasia and adeno-
carcinoma in Barrett’s oesophagus specimens, suggesting 
a field effect for carcinogenesis [60, 61]. The term ‘field 
of cancerisation’ was initially used by Slaughter et al. [62] 
when studying oral cancer. The authors summarised findings 
related to cancer developing in multifocal areas of precan-
cerous change, and abnormal tissue that surrounds tumour 
cells. Mechanisms that lead to an impairment of DNA dam-
age repair mechanisms in the tumour can show a field effect 
on the surrounding mucosa, which is facilitated by the adja-
cent inflammatory processes [63]. Reflux-related changes in 
the distal oesophagus increase the population of regulatory T 
cells and activate myeloid dendritic cells [64]. This cytokine 
increase supports epithelial mesenchymal transition in the 
distal oesophageal mucosa [65].
The loss of the p53 tumour suppressor gene has been 
studied extensively in patients who have already developed 
adenocarcinoma [66–68]. More research is necessary in p53 
behaviour in patients who have Barrett’s oesophagus without 
adenocarcinoma in vivo subjects [69].
Recognised biomarkers
There is a need for reliable biomarkers to aid diagnosis and 
distinguish which Barrett’s oesophagus patients are at risk 
of developing OAC [70]. This would potentially reduce the 
number of patients required to undertake endoscopy. Multi-
ple ongoing studies into establishing biomarkers reflects the 
fact that Barrett’s oesophagus needs a clinically validated 
prognostic tool to aid in defining risk [11]. Technology such 
as gene expression analysis, epigenetics and proteomics have 
been utilised to establish biomarkers in Barrett’s oesophagus 
and OAC [71]. Trefoil Factor 3 (TFF3) has been used in the 
Fig. 6   Photomicrograph of oesophageal adenocarcinoma (H&E 
×100 objective)
Clinical Journal of Gastroenterology 
1 3
cytosponge device providing presence or absence of Bar-
rett’s oesophagus with good affect (Table 3).
Mutations within p16 which result in clonal expansion 
have been found to be one of the earliest changes in Bar-
rett’s oesophagus [72, 73] p16 unfortunately has been not 
been shown to be associated with the grade of dysplasia 
[73]. Wong et al. [73] have interrogated other biomarkers for 
Barrett’s oesophagus which include the cell cycle markers 
Cyclin A and D. When present, they indicate inactivation of 
p105-Rb which restricts the cell’s ability to replicate DNA 
[73]. Studies are still preliminary.
Weaver et al. [47] assessed clonal structure using whole-
genome sequencing across common mutations in Barrett’s 
oesophagus, HGD and OAC samples. The authors estab-
lished the presence of SMAD4 clearly demonstrated risk 
of progression to cancer. It was, however, found at a low 
frequency within OAC tissue (13%). In this study, p53 was 
found to be mutated in both HGD (72%) and OAC (69%) 
samples, but only 1 case (2.5%) of ‘never-dysplastic’ 
oesophagus. This builds on previous work which has dem-
onstrated a significant increase in progression to OAC in 
those samples containing defects within the p53 gene [74].
The ideal biomarker has to be cost-effective, minimally 
invasive and superior to current diagnostics with multiple 
biopsies. Further research is necessary to build on risk 
stratifying Barrett’s oesophagus and aiding in prompt LGD 
and HGD diagnoses in these patients to reduce the burden 
of OAC developing in these patients. Identifying those at 
low risk would enable better risk stratification of patients, 
which could direct resources to patients who need treatment 
most. This would also eliminate unnecessary endoscopy. No 
clear data are available supporting the use of biomarkers or 
clinical features, which can sub-select those at higher risk of 
progression, other than an expert diagnosis of LGD.
Screening
Screening is based on the presence of multiple risk factors 
including chronic GORD, male sex, white race, patients over 
50 and a high BMI [17, 75]. A large number of asympto-
matic patients may miss the opportunity for their cancers to 
be detected early. Lagergren et al. [76] found that up to 40% 
of patients with OAC had no history of chronic GORD. Fur-
thermore, sampling and diagnostic errors with inter-variable 
pathological discrepancies results in a reduced effectiveness 
of screening [44].
The gold standard method of screening is visual OGD 
inspection and four quadrant biopsies of mucosal irregu-
larities in salmon-coloured mucosa above the OGJ at every 
1–2 cm interval using Seattle protocol [77]. This has been 
Table 3   Summary of molecular 
biomarkers [70, 74]
SIM specialised intestinal metaplasia, LGD low-grade dysplasia, HG: high-grade dysplasia, OAC oesopha-
geal adenocarcinoma, MCM2 minichromosome maintenance protein 2
Biomarker Sample size Baseline histology Endpoint
DNA abnormalities
 Aneuploidy/tetraploidy 322 SIM, indefinite, LGD OAC
Biomarker panels
 Loss of heterozygosity 243 SIM OAC
 Expert LGD, Aspergillus oryzae, 
lectin protein
380 SIM, indefinite, LGD OAC
 8 gene panel methylation 195 SIM HGD/OAC
Epigenetics
 p16 methylation 53 SIM, LGD HGD/OAC
Tumour suppressor loci
 p53 staining 48 LGD HGD/OAC
 p53 loss of heterozygosity 256 SIM, indefinite, LGD OAC
Cell cycle markers
 Cyclin A 48 SIM HGD/OAC
 Cyclin D1 307 SIM OAC
Clonal diversity
 Clonal diversity measures 239 SIM OAC
Proliferation
 MCM2 27 SIM OAC
Serum biomarkers
 Selenoprotein P 361 Variable OAC
 Leukocyte telomere length 300 Variable OAC
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clarified by NICE guidelines on management of dyspepsia 
published in 2014 [78]. They recommend that OGD should 
be considered if a patient with GORD has risk factors 
including older age, male gender and a history of reflux or 
others such as a long duration of symptoms, increased fre-
quency of symptoms, previous oesophagitis, previous hiatus 
hernia, oesophageal stricture or oesophageal ulcers.
Saad et al. [79] established that standard brush cytology 
demonstrated a high diagnostic accuracy for HGD/OAC 
(sensitivity 90%), moderate sensitivity for Barrett’s (60 
vs. 92%) and low sensitivity for LGD (20 vs. 97%) com-
pared with histology. Alexander et al. [80] commented that 
although brush cytology compliments histology there is an 
added increased cost with no true improvement. Standard 
OGD is expensive and associated with a small risk of com-
plications such as bleeding, perforation, aspiration and cardi-
opulmonary events [81]. Since OGD is not a suitable method 
for screening of large populations there exists a need for 
alternative, cheap, widely available, and an accurate method 
of screening [82].
The ACG has recommended unsedated transnasal endos-
copy as an alternative to traditional endoscopy for screening 
in Barrett’s oesophagus. Unsedated transnasal endoscopy is 
performed using an ultrathin endoscope using topical anaes-
thesia. Shariff et al. [83] reported that unsedated transnasal 
endoscopy was safer with fewer procedure- and sedation-
related complications compared to standard OGD. Jobe et al. 
[84] established the sensitivity for detection of columnar-
lined oesophagus was 98% and of intestinal metaplasia was 
91% and specificity was 100% with unsedated transnasal 
endoscopy compared to standard OGD.
Non-invasive methods such as the cytosponge or cap-
sular endoscopy have been utilised to screen for special-
ised intestinal metaplasia but do not alter the difficulty of 
sub-selecting a population with increased prevalence of 
specialised intestinal metaplasia or oesophageal adenocar-
cinoma. Cytosponge is a mesh surrounded by a gelatin cap-
sule attached to a string which is passed transorally [85]. 
The capsule dissolves in the proximal stomach 5 min post-
ingestion, expanding the mesh. The sample containing cyto-
logical specimen is stained with Trefoil Factor 3 (TFF3), 
which is a biomarker for specialised intestinal metaplasia. 
Kadri et al. [86] found that the cytosponge with TFF3 had a 
sensitivity of 73.3% (95% CI 44.9–92.2%) and specificity of 
93.8% (95% CI 91.3–95.8%) for detecting Barrett’s ≥1 cm 
of circumferential length. Heberle et al. [87] carried out a 
cost-analysis and established that screening GORD patients 
with cytosponge and following up positive results with OGD 
for confirmation reduced cost by 27–29% when compared 
with screening by OGD alone.
Capsule endoscopy allows oesophageal visualisation 
using wireless cameras without obtaining a biopsy. Capsule 
endoscopy has reported a sensitivity and specificity of 77 
and 86%, respectively, compared to standard OGD, but just 
73% specificity compared with histologically confirmed spe-
cialised intestinal metaplasia in a meta-analysis of 9 studies 
(n = 618) [88].
Liquid biopsies utilising blood samples and extracting 
circulating microRNAs expressed in disease are gaining 
promise as a screening tool. Bus et al. [89] profiled circulat-
ing microRNAs in patients with Barrett’s. The authors found 
that in 41 patients with Barrett’s and 15 controls, a panel 
of 4 circulating miRNAs (miRNA-95-3p, -136-5p, -194-5p, 
and -451a) distinguished Barrett’s oesophagus from controls 
with a sensitivity and specificity of 78 and 86%, respectively.
Surveillance
The primary aim of surveillance of Barrett’s oesophagus is 
to identify dysplasia and malignancy before distant disease 
has advanced. OAC usually presents with advanced disease 
as a result of early lymphovascular submucosal invasion 
[90]. OGD remains the primary method of surveillance 
using the Seattle protocol [91]. The frequency of surveil-
lance is determined by the degree of dysplasia encountered 
at biopsy which are subsequently then classified as per the 
Vienna classification [45]. It is important to note that sur-
veillance endoscopy should be performed in patients whose 
reflux symptoms are controlled, reducing the probability of 
reactive changes interfering with pathological interpretation 
[92].
In the United Kingdom, for non-dysplastic disease 
(metaplasia only), surveillance every 2–5 years is offered to 
patients. Worldwide guidelines differ with regards to differ-
ing Barrett’s oesophagus segment length. The BSG guide-
lines state that endoscopy should be repeated 3–5 years if 
the maximal length is less than 3 cm, and every 2–3 years 
if above or equal to 3 cm [16]. Evidence for improved out-
comes from surveillance is weak and remains the subject of 
debate. The UK multicentre BOSS trial aims to compare the 
benefits of 2-yearly surveillance endoscopy against endos-
copy on an ‘at need’ basis only.
Some literature does demonstrate a survival advantage 
in patients with Barrett’s undergoing surveillance. El Serag 
et al. [93] found that patients diagnosed with OAC during 
surveillance were detected at an earlier stage (stage 0–1: 
74.7 vs. 56.2; p < 0.001), survived longer (median 3.2 vs. 
2.3 years; p < 0.001), and had lower cancer-related mortal-
ity (34.0 vs. 54.0%, p < 0.0001) compared with those not in 
surveillance. As the natural course of Barrett’s in unknown, 
and surveillance is expensive and time-consuming, surveil-
lance has been the subject of much enquiry [94].
A cost-effective analysis of surveillance in patients with 
non-dysplastic disease at 5 yearly intervals was found not 
to be cost effective and that unless the annual progression 
rate to adenocarcinoma were 1.9% then a QALY (Quality 
Clinical Journal of Gastroenterology 
1 3
Adjusted Life Year) threshold of <$50,000 could not be 
achieved [95]. This finding is similar to previous studies 
highlighting that surveillance in this group is not cost-effec-
tive [91]. Findings such as inflammation and ulceration con-
sidered to be indefinite for dysplasia may evolve as a result 
of erosive oesophagitis. Acid suppression should be offered 
and a repeat endoscopy should be offered in 6 months [16].
If a histological finding of LGD is encountered, a repeat 
endoscopy should be performed at 6 months. If this confirms 
the diagnosis, discussions should be had regarding endo-
scopic surveillance (every 6 months for 2 years, annually 
thereafter) vs. eradication therapy (radiofrequency abla-
tion, endoscopic segmental resection, photodynamic ther-
apy, spray cryotherapy). The absolute benefit of eradication 
therapy for LGD is not certain, since the progression rate of 
LGD to OAC is low (approx. 5 per 1000 patient years) [96].
When HGD is encountered, two expert GI pathologists 
should analyse the samples and patients should be referred to 
a tertiary centre for consideration of repeat endoscopy, biop-
sies, endoscopic mucosal resection and eradication therapy 
(Fig. 7) [16].
Management
Patients with non-dysplastic Barrett’s oesophagus should 
be on acid suppression therapy. However, there is no con-
vincing evidence that this reverses specialised intestinal 
metaplasia [9]. LGD should be managed with endoscopic 
surveillance biopsies with endoscopic resection [17]. 
Endoscopic radiofrequency ablation (RFA) has been 
utilised in LGD patients. An American multicentre ret-
rospective cohort study discovered a 0.8% progression 
rate amongst patients with LGD diagnosed by expert 
pathologists and treated with RFA compared with 6.6% 
in the control surveillance group [97]. No clear data are 
available supporting the use of biomarkers or clinical fea-
tures which can sub-select those at higher risk of progres-
sion, other than an expert diagnosis of LGD. Patients with 
multifocal areas of dysplasia may have an increased risk 
of progression, as many patients with persistent LGD over 
time [98].
Upfront ablation has been shown to be a cost-effective 
strategy compared to intensive surveillance. A cost-effec-
tiveness analysis model stated that ablation with RFA in 
patients with LGD is more cost-effective than surveillance 
if ablation permanently eradicated LGD in more than 28% 
of patients, without the need for further surveillance in this 
group [99]. Previous BSG and AGA guidelines did not rec-
ommend ablation for LGD. The SURF (Surveillance vs. 
Radio Frequency ablation) trial randomised patients with 
LGD to RFA (n = 68) vs. intensive surveillance (n = 68). 
Results published in 2014 found that ablation reduced 
the risk of progression to HGD or adenocarcinoma from 
26.5% in the control arm to 1.5% in the RFA arm (95% CI 
14.1–35.9%, p > 0.001); 88.2% of intestinal metaplasia was 
eradicated and 92.6% of dysplasia using RFA, vs. rates of 0 
and 27.9% in the control arm [100].
Patients with HGD should be offered options including 
endoscopic therapies including RFA ± endoscopic mucosal 
resection, surgical resection, or intensive surveillance. 
There should be discussions involving the patient’s fitness 
for surgery and the patient’s desires. Ablative therapies treat 
entire Barrett’s oesophagus segments and surgery should 
only be necessary for patients with risk factors for lymph 
node metastases. Current standards reserve oesophagec-
tomy for patients with T1b invasion (submucosal invasion), 
Fig. 7   Surveillance and management for dysplasia (LGD/HGD)
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multifocal carcinoma or lesions that are not amenable to 
endoscopic resection [101].
A recent cost-effectiveness analysis was conducted for 
endoscopic eradication therapy (EET) for treatment of all 
grades of dysplasia in Barrett’s oesophagus patients [102]. 
EET for patients with LGD and HGD arising in Barrett’s 
oesophagus was deemed as cost-effective compared to endo-
scopic surveillance alone (lifetime £3,006 per QALY gained) 
by Pollit et al. [102] The authors further concluded that as 
the time elapses, the treatment becomes more cost-effective. 
The 5-year financial impact to the UK National Health Ser-
vice (NHS) of introducing EET is £7.1 m [102, 103].
Photodynamic treatment (PDT) using 5-aminolevulinic 
acid and porfimer sodium has been shown to be inferior 
to RFA. In a multicentre study by Overholt et al., 13% of 
patients progressed to adenocarcinoma despite treatment 
[104]. No studies with long-term follow-up have shown an 
improved overall survival of PDT vs. oesophagectomy [105]. 
The current guidelines state that patients should continue 
ongoing surveillance. There is no long-term data (>5 years) 
on the recurrence of intestinal metaplasia or dysplastic 
changes in squamous epithelium.
Imaging modalities in Barrett’s oesophagus
The need for an alternative non-invasive method of screen-
ing and/or surveillance could be highly beneficial reducing 
waiting times, alleviating patient fears and reducing future 
costs in modern healthcare. Thorough endoscopic assess-
ment and biopsies are key to a diagnosis of Barrett’s oesoph-
agus and subsequent surveillance. Most endoscopists appre-
ciate quadrantic biopsies are time-consuming and advanced 
imaging would be greatly beneficial.
High‑resolution endoscopy
High-resolution light endoscopy enhances mucosal visuali-
sation combining pixelated endoscopes (up to 1,000,000) 
with high definition screens. Studies have demonstrated a 
greater sensitivity in the detection of early neoplastic lesions 
when compared to standard endoscopy [106].
Chromoendoscopy
Chromoendoscopy is a diagnostic tool where a chemical 
substance is sprayed onto the mucosal surface to highlight 
specific areas of epithelia. The stains used can be subdivided 
into ‘absorptive’ (acetic acid, methylene blue, lugol solu-
tion) and ‘non-absorptive’ (indigo carmine) contrast stains. 
Advanced imaging modalities magnify the view and this 
subsequently increases the probability of finding suspicious 
lesions. Studies have demonstrated an increased diagnostic 
yield using Chromoendoscopy in recognising dysplasia in 
Barrett’s compared to random biopsies [107].
Acetic acid spraying with targeted biopsies has shown an 
increased detection rate of dysplasia and OAC, even with 
white light standard endoscopy [108]. Longcroft-Wheaton 
et al. [109] demonstrated that acetic acid chromoendoscopy 
yielded a 95.5% sensitivity and 80% specificity for the detec-
tion of OAC. Indigo carmine used as a non-absorptive con-
trast stain has shown to be highly sensitive (83%) and spe-
cific (88%) for HGD [110]. The agent is currently not able 
to differentiate between specialised intestinal metaplasia and 
dysplasia [111].
Autofluorescence
Autofluorescence imaging endoscopy utilises short wave-
lengths of light to stimulate endogenous substances (nico-
tinamide adenine dinucleotide (NADH), collagen, aromatic 
amino acids and porphyrines) in tissue to emit fluorescent 
light of a longer wavelength [112]. This interrogates the 
tissue at depth and aids interpretation of vasculature and 
topography [113]. Studies have not demonstrated the supe-
riority of this method compared with high resolution endos-
copy alone for the detection of dysplasia [114, 115]. Conse-
quently, autofluorescence guided biopsies are not currently 
employed in hospitals in the United Kingdom.
Narrow‑band imaging (NBI)
Narrow-band imaging allows visualisation of the superficial 
mucosa and vasculature without the need for any additional 
dyes. The system illuminates the mucosa with blue and 
green wavelength light, thus demonstrating tissue vascu-
lature. A meta-analysis by Mannath et al. [116] evaluated 
446 patients. For diagnosing HGD, the pooled sensitivity 
and specificity were 0.96 (95% confidence interval [CI] 
0.93–0.99) and 0.94 (95% CI 0.84–1.0) on a per-lesion anal-
ysis with similar results on per-patient analysis. For special-
ised intestinal metaplasia characterisation, the pooled sensi-
tivity and specificity were 0.95 (95% CI 0.87–1.0) and 0.65 
(95% CI 0.52–0.78) on a per-lesion analysis. The authors 
concluded that magnified NBI is accurate with high diag-
nostic precision for diagnosis of HGD in Barrett’s oesopha-
gus. They further commented that NBI has high sensitivity 
but poor specificity for characterising specialised intestinal 
metaplasia.
Optical coherence tomography (OCT)
Optical coherence tomography (OCT) utilises electro-
magnetic (EM) waves to generate images based on the 
detection of reflected light. Resolutions up to 10–25 µm 
enables the identification of microscopic features such as 
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lymphovascular structures [117]. Robles et al. [118] inter-
rogated 19 studies (17 in vivo; 2 ex vivo). The authors found 
an excellent diagnostic yield for specialised intestinal meta-
plasia detection but not for dysplasia. Evans et al. [119] 
only demonstrated an 83% sensitivity and 75% specificity 
between differentiating HGD and OAC.
Confocal fluorescence microendoscopy
This diagnostic tool images fluorophores within the cell 
microstructure and generates a histological image [120]. 
Kara et al. [121] evaluated 63 patients in ex vivo samples. 
The authors concluded that a differentiation could be made 
between Barrett’s oesophagus and HGD, but that a diagnosis 
of dysplasia needed histological guidance.
Curvers et al. [122] concluded that the above enhanced 
imaging techniques may be no better than using high-qual-
ity white light imaging. Furthermore, these methods fail to 
achieve the aim of replacing random biopsies and histology 
for diagnosis. This opens the door for innovative diagnostic, 
screening and surveillance modalities to be explored in the 
field of Barrett’s oesophagus and its subsequent transforma-
tion to OAC.
Future developments
High-quality white light imaging with OGD and biopsy 
remains the gold standard of diagnosis and surveillance. 
Dysplasia and p53 accumulation appear to be an earlier 
and more sensitive markers of malignant potential in Bar-
rett’s oesophagus. There remains substantial inter-observer 
variability with regards to the grading of dysplasia between 
pathologists. Improving the diagnosis of dysplasia and 
categorising patients at an early stage of disease is highly 
encouraged. There is an additional need for reliable bio-
markers in being able to aid diagnosis and potentially reduce 
the number of patients required to undertake endoscopy 
[70]. Multiple ongoing studies into establishing biomarkers 
reflects the fact that Barrett’s oesophagus needs a clinically 
validated prognostic tool to aid in defining risk [123]. If a 
marker were to be isolated that indicated the propensity to 
dysplasia, this could establish why some patients progress 
to dysplasia and, therefore, aid in identifying preventative 
measures.
Very few potential diagnostic and prognostic biomark-
ers have been shown to be reproducible and robust [70]. 
Immunohistochemistry studies of nuclear p53 expression in 
patients with Barrett’s oesophagus have shown to improve 
inter-observer variability in diagnosing dysplasia and can 
predict progression risk with an OR of 3–8 [124, 125]. Many 
studies have investigated genetics and epigenetics in rela-
tion to Barrett’s oesophagus and its progression to OAC 
[126–128]. However, a paucity of evidence for other epige-
netic markers and the absence of robust validation methods 
limit the conclusions that can be drawn from such literature 
[129].
Vibrational spectroscopy
Vibrational spectroscopy techniques such as Fourier-trans-
form infrared (FTIR) spectroscopy or Raman spectroscopy 
(RS) are used to study interactions of light with biologi-
cal materials and are relatively novel [130]. Advantages of 
spectrochemical analysis are its low cost, minimal sample 
preparation, non-destructive nature and substantially accu-
rate results [131]. Biospectroscopy for disease diagnosis and 
screening is possible in a wide range of conditions including 
cancer. Further substantial prospective trials are necessary to 
delineate whether biospectroscopy has the ability to identify 
the small number of at-risk individuals amongst the large 
number not requiring follow-up [132].
Vibrational spectroscopic techniques have been used to 
delineate classification of oesophageal tissue from Barrett’s 
oesophagus through to OAC. Old et al. [133] identified key 
biochemical differences categorised spectral signatures 
using ATR-FTIR spectroscopy in ex vivo samples: high 
glycogen content was seen in normal squamous tissue, high 
glycoprotein content was observed in glandular Barrett’s 
oesophagus tissue, and high DNA content was observed 
in dysplastic tissue/OAC samples. Classification of normal 
squamous samples vs. ’abnormal’ samples (any stage of 
Barrett’s oesophagus) was performed with 100% sensitiv-
ity and specificity. Neoplastic Barrett’s (dysplasia or OAC) 
oesophagus was identified with 95.6% sensitivity and 86.4% 
specificity [133].
In vivo RS has been utilised in the field of OAC. Sensi-
tivities and specificities of up to 95% have been established 
for an in vivo diagnosis of HGD and OAC using multimodal 
image-guided Raman endoscopy techniques [134, 135]. 
Non-endoscopic approaches remain to be validated in large 
populations in terms of accuracy and cost effectiveness. 
Novel non-invasive markers identifiable in biofluids would 
be ideal for widespread application, but are currently not 
available. The use of vibrational spectroscopy in biofluids 
has been shown to be promising in categorising disease pro-
cesses from Barrett’s oesophagus to OAC [136, 137]. This 
needs further, prospective multicentre studies for clinical 
validation.
Conclusion
Barrett’s oesophagus is the only known precursor to OAC 
with a population prevalence of around 1–2% [3]. Estab-
lished risk factors include older age, male gender and a 
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history of reflux symptoms [8]. Although guidelines on the 
screening and surveillance exist in Barrett’s oesophagus, 
the current strategies are inadequate as more than 90% of 
patients diagnosed with OAC do not have a preceding diag-
nosis of Barrett’s oesophagus [138]. Furthermore, the annual 
risk for developing OAC has been shown in large population 
studies to be as low as 0.16% [139].
OGD is the gold standard method in screening for Bar-
rett’s oesophagus. This invasive method is expensive with 
risks associated negating its use as a current screening tool. 
The need for an alternative, non-invasive method of screen-
ing and/or surveillance would be highly beneficial in reduc-
ing waiting times, alleviating patient fears and reducing 
future costs in worldwide healthcare sectors. Vibrational 
spectroscopy in biofluids has shown promise in categorising 
disease processes from Barrett’s oesophagus to OAC [136, 
137]. This needs further, prospective multicentre studies for 
clinical validation.
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